BioCardia, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
BioCardia, Inc. (BCDA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $109.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-12
- BioCardia, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $109.00K, a 11.22% increase year-over-year.
- BioCardia, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $113.00K, a 33.53% decline year-over-year.
- BioCardia, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $77.00K, a 56.50% decline year-over-year.
- BioCardia, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $98.00K, a 46.74% decline year-over-year.
- BioCardia, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $430.00K, a 41.97% decline from fiscal 2024.
- BioCardia, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $741.00K, a 28.06% decline from fiscal 2023.
- BioCardia, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $1.03M, a 12.93% decline from fiscal 2022.
- BioCardia, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $1.18M, a 28.78% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $109.00K 10-Q · filed 2026-08-12 | $222.00K derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2026-03-31 | $113.00K 10-Q · filed 2026-08-12 | |||
| 2025-12-31 | $430.00K 10-K · filed 2026-03-24 | |||
| 2025-09-30 | $77.00K 10-Q · filed 2025-11-12 | $175.00K derived: sum of 2 quarters · filed 2026-08-12 | $345.00K derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-06-30 | $98.00K 10-Q · filed 2026-08-12 | $268.00K derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $170.00K 10-Q · filed 2026-08-12 | |||
| 2024-12-31 | $741.00K 10-K · filed 2026-03-24 | |||
| 2024-09-30 | $177.00K 10-Q · filed 2025-11-12 | $361.00K derived: sum of 2 quarters · filed 2025-11-12 | $565.00K derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | $184.00K 10-Q · filed 2025-11-12 | $388.00K derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | $204.00K 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $1.03M 10-K · filed 2025-03-26 | |||
| 2023-09-30 | $251.00K 10-Q · filed 2024-11-13 | $568.00K derived: sum of 2 quarters · filed 2024-11-13 | $846.00K derived: sum of 3 quarters · filed 2024-11-13 | |
| 2023-06-30 | $317.00K 10-Q · filed 2024-11-13 | $595.00K derived: sum of 2 quarters · filed 2024-11-13 | ||
| 2023-03-31 | $278.00K 10-Q · filed 2024-11-13 | |||
| 2022-12-31 | $1.18M 10-K · filed 2024-03-27 | |||
| 2022-09-30 | $280.00K 10-Q · filed 2023-11-08 | $584.00K derived: sum of 2 quarters · filed 2023-11-08 | $903.00K derived: sum of 3 quarters · filed 2023-11-08 | |
| 2022-06-30 | $304.00K 10-Q · filed 2023-11-08 | $623.00K derived: sum of 2 quarters · filed 2023-11-08 | ||
| 2022-03-31 | $319.00K 10-Q · filed 2023-11-08 | |||
| 2021-12-31 | $1.66M 10-K · filed 2023-03-29 | |||
| 2021-09-30 | $437.00K 10-Q · filed 2022-11-09 | $821.00K derived: sum of 2 quarters · filed 2022-11-09 | $1.24M derived: sum of 3 quarters · filed 2022-11-09 | |
| 2021-06-30 | $384.00K 10-Q · filed 2022-11-09 | $800.00K derived: sum of 2 quarters · filed 2022-11-09 | ||
| 2021-03-31 | $416.00K 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $2.95M 10-K · filed 2022-03-29 | |||
| 2020-09-30 | $737.00K 10-Q · filed 2021-11-10 | $1.39M derived: sum of 2 quarters · filed 2021-11-10 | $2.33M derived: sum of 3 quarters · filed 2021-11-10 | |
| 2020-06-30 | $655.00K 10-Q · filed 2021-11-10 | $1.60M derived: sum of 2 quarters · filed 2021-11-10 | ||
| 2020-03-31 | $941.00K 10-Q · filed 2021-11-10 | |||
| 2019-12-31 | $2.72M 10-K · filed 2021-03-30 | |||
| 2019-09-30 | $756.00K 10-Q · filed 2020-11-10 | $1.45M derived: sum of 2 quarters · filed 2020-11-10 | $2.14M derived: sum of 3 quarters · filed 2020-11-10 | |
| 2019-06-30 | $696.00K 10-Q · filed 2020-11-10 | $1.39M derived: sum of 2 quarters · filed 2020-11-10 | ||
| 2019-03-31 | $690.00K 10-Q · filed 2020-11-10 | |||
| 2018-12-31 | $2.77M 10-K · filed 2020-04-09 | |||
| 2018-09-30 | $730.00K 10-Q · filed 2019-11-19 | $1.47M derived: sum of 2 quarters · filed 2019-11-19 | $2.08M derived: sum of 3 quarters · filed 2019-11-19 | |
| 2018-06-30 | $738.00K 10-Q · filed 2019-11-19 | $1.35M derived: sum of 2 quarters · filed 2019-11-19 | ||
| 2018-03-31 | $615.00K 10-Q · filed 2019-11-19 | |||
| 2017-12-31 | $2.71M 10-K · filed 2020-04-09 | |||
| 2016-12-31 | $942.00K 10-K · filed 2019-04-02 | |||
| 2015-12-31 | $283.00K 10-K · filed 2018-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |